2010
DOI: 10.1016/j.jsbmb.2010.02.035
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of 2β-substituted-14-epi-previtamin D3 and testing of its genomic activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2010
2010
2022
2022

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 22 publications
0
2
0
Order By: Relevance
“…Figure 19 (2009-2010) [271][272][273][274][275][276][277][278][279][280][281][282][283]. Intensive research activity was carried out on Gemini compounds 1053-1069 [273].…”
Section: Resultsmentioning
confidence: 99%
“…Figure 19 (2009-2010) [271][272][273][274][275][276][277][278][279][280][281][282][283]. Intensive research activity was carried out on Gemini compounds 1053-1069 [273].…”
Section: Resultsmentioning
confidence: 99%
“…As crystallographic studies revealed the presence of several water molecules near the A-ring which link the ligand C-2 position to the protein surface [17], the effect of C-2 substitutions in 14-epi-1,25(OH) 2 -previtamin D 3 was evaluated. Several analogs with different substituents at C-2 were synthesized and their affinity to VDR as well as their potency to transactivate the osteocalcin promoter was evaluated [15,16]. 14-Epi-1,25(OH) 2 -previtamin D 3 itself had a 200-fold lower affinity for VDR and the EC 50 -concentration for transactivation of the osteocalcin promoter was 15-fold higher than that of 1,25(OH) 2 D 3 .…”
Section: Introductionmentioning
confidence: 99%